aluates Reports

$ 0.0

Automative

Global BRAF(V600E) Kinase Inhibitors Market Research Report 2024

Published Date: October 2024

Report Code: QYRE-Auto-36N18310

BUY CHAPTERS

Global BRAF(V600E) Kinase Inhibitors Market Research Report 2024

Code: QYRE-Auto-36N18310

Report

October 2024

Pages:69

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Novartis

Pfizer Inc

BRAF(V600E) Kinase Inhibitors Market Size

Kinase Inhibitors market was valued at US$ 1411 million in 2023 and is anticipated to reach US$ 2136 million by 2030, witnessing a CAGR of 6.1% during the forecast period 2024-2030.

BRAF(V600E) Kinase Inhibitors Market

BRAF(V600E) kinase inhibitors are targeted therapies designed to inhibit the activity of the mutated BRAF protein, specifically the V600E variant, which is associated with various cancers, including melanoma, colorectal cancer, and thyroid cancer.By selectively blocking the activity of the BRAF(V600E) protein, these inhibitors—such as vemurafenib and dabrafenib—can effectively reduce tumor size, slow disease progression, and improve overall survival in affected patients.

The global BRAF(V600E)

The development of BRAF(V600E) kinase inhibitors has significantly transformed the treatment landscape for melanoma and other BRAF-mutated cancers. Initially, vemurafenib emerged as a breakthrough therapy, demonstrating impressive response rates in patients with metastatic melanoma harboring the BRAF V600E mutation. Its approval in 2011 marked a turning point, highlighting the potential of targeted therapies in oncology and setting a precedent for future drug development in this area.

Following the success of vemurafenib, the focus shifted to improving treatment efficacy and overcoming resistance mechanisms. This led to the development of second-generation BRAF inhibitors, such as dabrafenib, which not only offered enhanced potency but also improved tolerability. Moreover, the combination of BRAF inhibitors with MEK inhibitors, like trametinib, became a key strategy to synergistically inhibit the MAPK pathway, reducing the risk of resistance and enhancing clinical outcomes.

Additionally, there is a growing interest in exploring combinations with immunotherapies and other targeted agents to optimize patient outcomes. As the understanding of tumor biology deepens, the future of BRAF(V600E) inhibitors will likely involve more innovative and personalized approaches, further advancing the management of melanoma and other BRAF-related malignancies.

Report Scope

This report aims to provide a comprehensive presentation of the global market for BRAF(V600E) Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding BRAF(V600E) Kinase Inhibitors.

The BRAF(V600E) Kinase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global BRAF(V600E) Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the BRAF(V600E) Kinase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of BRAF(V600E) Kinase Inhibitors Market Report

Report Metric	Details
Report Name	BRAF(V600E) Kinase Inhibitors Market
Accounted market size in 2023	US$ 1411 million
Forecasted market size in 2030	US$ 2136 million
CAGR	6.1%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Vemurafenib Dabrafenib Encorafenib Other
Segment by Application	Melanoma Non-small Cell Lung Cancer Erdheim-Chester Disease Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche, Novartis, Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of BRAF(V600E) Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of BRAF(V600E) Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is BRAF(V600E) Kinase Inhibitors Market growing?

Ans: The BRAF(V600E) Kinase Inhibitors Market witnessing a CAGR of 6.1% during the forecast period 2024-2030.

What is the BRAF(V600E) Kinase Inhibitors Market size in 2030?

Ans: The BRAF(V600E) Kinase Inhibitors Market size in 2030 will be US$ 2136 million.

Who are the main players in the BRAF(V600E) Kinase Inhibitors Market report?

Ans: The main players in the BRAF(V600E) Kinase Inhibitors Market are Roche, Novartis, Pfizer

What are the Application segmentation covered in the BRAF(V600E) Kinase Inhibitors Market report?

Ans: The Applications covered in the BRAF(V600E) Kinase Inhibitors Market report are Melanoma, Non-small Cell Lung Cancer, Erdheim-Chester Disease, Other

What are the Type segmentation covered in the BRAF(V600E) Kinase Inhibitors Market report?

Ans: The Types covered in the BRAF(V600E) Kinase Inhibitors Market report are Vemurafenib, Dabrafenib, Encorafenib, Other

Recommended Reports

Kinase Inhibitors

Melanoma Markets

Targeted Therapies

1 BRAF(V600E) Kinase Inhibitors Market Overview

1.1 Product Definition

1.2 BRAF(V600E) Kinase Inhibitors by Type

1.2.1 Global BRAF(V600E) Kinase Inhibitors Market Value Comparison by Type (2024-2030)

1.2.2 Vemurafenib

1.2.3 Dabrafenib

1.2.4 Encorafenib

1.2.5 Other

1.3 BRAF(V600E) Kinase Inhibitors by Application

1.3.1 Global BRAF(V600E) Kinase Inhibitors Market Value by Application (2024-2030)

1.3.2 Melanoma

1.3.3 Non-small Cell Lung Cancer

1.3.4 Erdheim-Chester Disease

1.3.5 Other

1.4 Global BRAF(V600E) Kinase Inhibitors Market Size Estimates and Forecasts

1.4.1 Global BRAF(V600E) Kinase Inhibitors Revenue 2019-2030

1.4.2 Global BRAF(V600E) Kinase Inhibitors Sales 2019-2030

1.4.3 Global BRAF(V600E) Kinase Inhibitors Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 BRAF(V600E) Kinase Inhibitors Market Competition by Manufacturers

2.1 Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Manufacturers (2019-2024)

2.2 Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Manufacturers (2019-2024)

2.3 Global BRAF(V600E) Kinase Inhibitors Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of BRAF(V600E) Kinase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of BRAF(V600E) Kinase Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of BRAF(V600E) Kinase Inhibitors, Product Type & Application

2.7 Global Key Manufacturers of BRAF(V600E) Kinase Inhibitors, Date of Enter into This Industry

2.8 Global BRAF(V600E) Kinase Inhibitors Market Competitive Situation and Trends

2.8.1 Global BRAF(V600E) Kinase Inhibitors Market Concentration Rate

2.8.2 The Global 5 and 10 Largest BRAF(V600E) Kinase Inhibitors Players Market Share by Revenue

2.8.3 Global BRAF(V600E) Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global BRAF(V600E) Kinase Inhibitors Market Scenario by Region

3.1 Global BRAF(V600E) Kinase Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global BRAF(V600E) Kinase Inhibitors Sales by Region: 2019-2030

3.2.1 Global BRAF(V600E) Kinase Inhibitors Sales by Region: 2019-2024

3.2.2 Global BRAF(V600E) Kinase Inhibitors Sales by Region: 2025-2030

3.3 Global BRAF(V600E) Kinase Inhibitors Revenue by Region: 2019-2030

3.3.1 Global BRAF(V600E) Kinase Inhibitors Revenue by Region: 2019-2024

3.3.2 Global BRAF(V600E) Kinase Inhibitors Revenue by Region: 2025-2030

3.4 North America BRAF(V600E) Kinase Inhibitors Market Facts & Figures by Country

3.4.1 North America BRAF(V600E) Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2030)

3.4.3 North America BRAF(V600E) Kinase Inhibitors Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe BRAF(V600E) Kinase Inhibitors Market Facts & Figures by Country

3.5.1 Europe BRAF(V600E) Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2030)

3.5.3 Europe BRAF(V600E) Kinase Inhibitors Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific BRAF(V600E) Kinase Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific BRAF(V600E) Kinase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific BRAF(V600E) Kinase Inhibitors Sales by Region (2019-2030)

3.6.3 Asia Pacific BRAF(V600E) Kinase Inhibitors Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America BRAF(V600E) Kinase Inhibitors Market Facts & Figures by Country

3.7.1 Latin America BRAF(V600E) Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2030)

3.7.3 Latin America BRAF(V600E) Kinase Inhibitors Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa BRAF(V600E) Kinase Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa BRAF(V600E) Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2030)

3.8.3 Middle East and Africa BRAF(V600E) Kinase Inhibitors Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global BRAF(V600E) Kinase Inhibitors Sales by Type (2019-2030)

4.1.1 Global BRAF(V600E) Kinase Inhibitors Sales by Type (2019-2024)

4.1.2 Global BRAF(V600E) Kinase Inhibitors Sales by Type (2025-2030)

4.1.3 Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Type (2019-2030)

4.2 Global BRAF(V600E) Kinase Inhibitors Revenue by Type (2019-2030)

4.2.1 Global BRAF(V600E) Kinase Inhibitors Revenue by Type (2019-2024)

4.2.2 Global BRAF(V600E) Kinase Inhibitors Revenue by Type (2025-2030)

4.2.3 Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Type (2019-2030)

4.3 Global BRAF(V600E) Kinase Inhibitors Price by Type (2019-2030)

5 Segment by Application

5.1 Global BRAF(V600E) Kinase Inhibitors Sales by Application (2019-2030)

5.1.1 Global BRAF(V600E) Kinase Inhibitors Sales by Application (2019-2024)

5.1.2 Global BRAF(V600E) Kinase Inhibitors Sales by Application (2025-2030)

5.1.3 Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Application (2019-2030)

5.2 Global BRAF(V600E) Kinase Inhibitors Revenue by Application (2019-2030)

5.2.1 Global BRAF(V600E) Kinase Inhibitors Revenue by Application (2019-2024)

5.2.2 Global BRAF(V600E) Kinase Inhibitors Revenue by Application (2025-2030)

5.2.3 Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Application (2019-2030)

5.3 Global BRAF(V600E) Kinase Inhibitors Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche BRAF(V600E) Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Roche BRAF(V600E) Kinase Inhibitors Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis BRAF(V600E) Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Novartis BRAF(V600E) Kinase Inhibitors Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Company Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer BRAF(V600E) Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Pfizer BRAF(V600E) Kinase Inhibitors Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 BRAF(V600E) Kinase Inhibitors Industry Chain Analysis

7.2 BRAF(V600E) Kinase Inhibitors Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 BRAF(V600E) Kinase Inhibitors Production Mode & Process

7.4 BRAF(V600E) Kinase Inhibitors Sales and Marketing

7.4.1 BRAF(V600E) Kinase Inhibitors Sales Channels

7.4.2 BRAF(V600E) Kinase Inhibitors Distributors

7.5 BRAF(V600E) Kinase Inhibitors Customers

8 BRAF(V600E) Kinase Inhibitors Market Dynamics

8.1 BRAF(V600E) Kinase Inhibitors Industry Trends

8.2 BRAF(V600E) Kinase Inhibitors Market Drivers

8.3 BRAF(V600E) Kinase Inhibitors Market Challenges

8.4 BRAF(V600E) Kinase Inhibitors Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Roche

Novartis

Pfizer Inc

List of Tables

Table 1. Global BRAF(V600E) Kinase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global BRAF(V600E) Kinase Inhibitors Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global BRAF(V600E) Kinase Inhibitors Market Competitive Situation by Manufacturers in 2023

Table 4. Global BRAF(V600E) Kinase Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Manufacturers (2019-2024)

Table 6. Global BRAF(V600E) Kinase Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global BRAF(V600E) Kinase Inhibitors Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market BRAF(V600E) Kinase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of BRAF(V600E) Kinase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of BRAF(V600E) Kinase Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of BRAF(V600E) Kinase Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of BRAF(V600E) Kinase Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global BRAF(V600E) Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in BRAF(V600E) Kinase Inhibitors as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global BRAF(V600E) Kinase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global BRAF(V600E) Kinase Inhibitors Sales by Region (2019-2024) & (K Units)

Table 18. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Region (2019-2024)

Table 19. Global BRAF(V600E) Kinase Inhibitors Sales by Region (2025-2030) & (K Units)

Table 20. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Region (2025-2030)

Table 21. Global BRAF(V600E) Kinase Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Region (2019-2024)

Table 23. Global BRAF(V600E) Kinase Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Region (2025-2030)

Table 25. North America BRAF(V600E) Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 27. North America BRAF(V600E) Kinase Inhibitors Sales by Country (2025-2030) & (K Units)

Table 28. North America BRAF(V600E) Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America BRAF(V600E) Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe BRAF(V600E) Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 32. Europe BRAF(V600E) Kinase Inhibitors Sales by Country (2025-2030) & (K Units)

Table 33. Europe BRAF(V600E) Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe BRAF(V600E) Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific BRAF(V600E) Kinase Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific BRAF(V600E) Kinase Inhibitors Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific BRAF(V600E) Kinase Inhibitors Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific BRAF(V600E) Kinase Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific BRAF(V600E) Kinase Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America BRAF(V600E) Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 42. Latin America BRAF(V600E) Kinase Inhibitors Sales by Country (2025-2030) & (K Units)

Table 43. Latin America BRAF(V600E) Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America BRAF(V600E) Kinase Inhibitors Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa BRAF(V600E) Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa BRAF(V600E) Kinase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa BRAF(V600E) Kinase Inhibitors Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa BRAF(V600E) Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa BRAF(V600E) Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global BRAF(V600E) Kinase Inhibitors Sales (K Units) by Type (2019-2024)

Table 51. Global BRAF(V600E) Kinase Inhibitors Sales (K Units) by Type (2025-2030)

Table 52. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Type (2019-2024)

Table 53. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Type (2025-2030)

Table 54. Global BRAF(V600E) Kinase Inhibitors Revenue (US$ Million) by Type (2019-2024)

Table 55. Global BRAF(V600E) Kinase Inhibitors Revenue (US$ Million) by Type (2025-2030)

Table 56. Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Type (2019-2024)

Table 57. Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Type (2025-2030)

Table 58. Global BRAF(V600E) Kinase Inhibitors Price (US$/Unit) by Type (2019-2024)

Table 59. Global BRAF(V600E) Kinase Inhibitors Price (US$/Unit) by Type (2025-2030)

Table 60. Global BRAF(V600E) Kinase Inhibitors Sales (K Units) by Application (2019-2024)

Table 61. Global BRAF(V600E) Kinase Inhibitors Sales (K Units) by Application (2025-2030)

Table 62. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Application (2019-2024)

Table 63. Global BRAF(V600E) Kinase Inhibitors Sales Market Share by Application (2025-2030)

Table 64. Global BRAF(V600E) Kinase Inhibitors Revenue (US$ Million) by Application (2019-2024)

Table 65. Global BRAF(V600E) Kinase Inhibitors Revenue (US$ Million) by Application (2025-2030)

Table 66. Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Application (2019-2024)

Table 67. Global BRAF(V600E) Kinase Inhibitors Revenue Market Share by Application (2025-2030)

Table 68. Global BRAF(V600E) Kinase Inhibitors Price (US$/Unit) by Application (2019-2024)

Table 69. Global BRAF(V600E) Kinase Inhibitors Price (US$/Unit) by Application (2025-2030)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche BRAF(V600E) Kinase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Roche BRAF(V600E) Kinase Inhibitors Product

Table 74. Roche Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis BRAF(V600E) Kinase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Novartis BRAF(V600E) Kinase Inhibitors Product

Table 79. Novartis Recent Developments/Updates

Table 80. Pfizer Company Information

Table 81. Pfizer Description and Business Overview

Table 82. Pfizer BRAF(V600E) Kinase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Pfizer BRAF(V600E) Kinase Inhibitors Product

Table 84. Pfizer Recent Developments/Updates

Table 85. Key Raw Materials Lists

Table 86. Raw Materials Key Suppliers Lists

Table 87. BRAF(V600E) Kinase Inhibitors Distributors List

Table 88. BRAF(V600E) Kinase Inhibitors Customers List

Table 89. BRAF(V600E) Kinase Inhibitors Market Trends

Table 90. BRAF(V600E) Kinase Inhibitors Market Drivers

Table 91. BRAF(V600E) Kinase Inhibitors Market Challenges

Table 92. BRAF(V600E) Kinase Inhibitors Market Restraints

Table 93. Research Programs/Design for This Report

Table 94. Key Data Information from Secondary Sources

Table 95. Key Data Information from Primary Sources

Table 96. Authors List of This Report

List of Figures

Figure 1. Product Picture of BRAF(V600E) Kinase Inhibitors

Figure 2. Global BRAF(V600E) Kinase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global BRAF(V600E) Kinase Inhibitors Market Share by Type: 2023 & 2030

Figure 4. Vemurafenib Product Picture

Figure 5. Dabrafenib Product Picture

Figure 6. Encorafenib Product Picture

Figure 7. Other Product Picture

Figure 8. Global BRAF(V600E) Kinase Inhibitors Market Value by Application (2024-2030) & (US$ Million)

Figure 9. Global BRAF(V600E) Kinase Inhibitors Market Share by Application: 2023 & 2030

Figure 10. Melanoma

Figure 11. Non-small Cell Lung Cancer

Figure 12. Erdheim-Chester Disease

Figure 13. Other

Figure 14. Global BRAF(V600E) Kinase Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global BRAF(V600E) Kinase Inhibitors Market Size (2019-2030) & (US$ Million)

Figure 16. Global BRAF(V600E) Kinase Inhibitors Sales (2019-2030) & (K Units)

Figure 17. Global BRAF(V600E) Kinase Inhibitors Average Price (US$/Unit) & (2019-2030)

Figure 18. BRAF(V600E) Kinase Inhibitors Report Years Considered

Figure 19. BRAF(V600E) Kinase Inhibitors Sales Share by Manufacturers in 2023

Figure 20. Global BRAF(V600E) Kinase Inhibitors Revenue Share by Manufacturers in 2023

Figure 21. Global 5 and 10 Largest BRAF(V600E) Kinase Inhibitors Players: Market Share by Revenue in BRAF(V600E) Kinase Inhibitors in 2023

Figure 22. BRAF(V600E) Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 23. Global BRAF(V600E) Kinase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 24. North America BRAF(V600E) Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 25. North America BRAF(V600E) Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 26. United States BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Canada BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Europe BRAF(V600E) Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 29. Europe BRAF(V600E) Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 30. Germany BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. France BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. U.K. BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Italy BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Russia BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Asia Pacific BRAF(V600E) Kinase Inhibitors Sales Market Share by Region (2019-2030)

Figure 36. Asia Pacific BRAF(V600E) Kinase Inhibitors Revenue Market Share by Region (2019-2030)

Figure 37. China BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Japan BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. South Korea BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. India BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Australia BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. China Taiwan BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Southeast Asia BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Latin America BRAF(V600E) Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 45. Mexico BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Brazil BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Argentina BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Colombia BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Middle East and Africa BRAF(V600E) Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 50. Middle East and Africa BRAF(V600E) Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 51. Turkey BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Saudi Arabia BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. UAE BRAF(V600E) Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Global Sales Market Share of BRAF(V600E) Kinase Inhibitors by Type (2019-2030)

Figure 55. Global Revenue Market Share of BRAF(V600E) Kinase Inhibitors by Type (2019-2030)

Figure 56. Global BRAF(V600E) Kinase Inhibitors Price (US$/Unit) by Type (2019-2030)

Figure 57. Global Sales Market Share of BRAF(V600E) Kinase Inhibitors by Application (2019-2030)

Figure 58. Global Revenue Market Share of BRAF(V600E) Kinase Inhibitors by Application (2019-2030)

Figure 59. Global BRAF(V600E) Kinase Inhibitors Price (US$/Unit) by Application (2019-2030)

Figure 60. BRAF(V600E) Kinase Inhibitors Value Chain

Figure 61. BRAF(V600E) Kinase Inhibitors Production Process

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Combination Therapy with BRAF and MEK Inhibitors Market Research Report 2024

Global BRAF Kinase Inhibitors Market Insights Forecast to 2030

Global Targeted Therapy Drugs for Melanoma Market Research Report 2024

Global KRAS Inhibitor Market Research Report 2024

Global MEK Inhibitor Market Research Report 2024

Global Kinase Inhibitors For Cancer Treatment Market Research Report 2024

Global Combination Therapies for Melanoma Market Research Report 2024

Global Targeted Drug BRAF Inhibitors for NSCLC Market Research Report 2024

Global ALK Inhibitors Market Research Report 2024

Global RET Inhibitors Market Research Report 2024

Global VEGF Inhibitors for Cancer Market Research Report 2024

Global Regorafenib Drugs Market Research Report 2024

Global CDK4 6 Inhibitors Market Research Report 2024

Global Saracatinib Market Research Report 2024

Global KRAS G12C Inhibitors Market Research Report 2024

Global Vandetanib Tablets Market Research Report 2024

Global Medicine for the Treatment of Advanced Thyroid Cancer Market Research Report 2024

Global Fedratinib Market Research Report 2024

Global PARP Poly ADP Ribose Polymerase Inhibitor Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions